Poly Medicure earnings calls.
Other · 4 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹535 Cr
verified financial record
Quarters tracked
4
source records in the directory
Delivery assessment
0
Across 12 tracked commitments: 0 delivered, 12 missed.
Call date
Pending
latest available source date
Signal trajectory
3 actual quartersCurrent read
0/100
Across 12 tracked commitments: 0 delivered, 12 missed.
Latest source read
What changed this quarter?
Poly Medicure reported Q1 FY26 consolidated revenue of Rs 403 crore (5% YoY), with EBITDA at Rs 106 crore (26.3% margin) and PAT at Rs 93 crore (up 25.7% YoY). Domestic business outperformed with 20% growth to Rs 126 crore, driven by 25% private sector growth, partially offset by 10% government segment decline. International revenue declined 1% to Rs 275 crore, with Europe down 6.7% due to inventory destocking and Chinese dumping. The company signed two CDMO contracts (US and Hong Kong-based) for vascular access and pain management products, with revenues expected from FY27. New cardiology vertical deployed 1,350 stents with plans to reach 20,000 units by year-end. Management lowered international growth guidance to 5-10% (from 12-15%) citing geopolitical uncertainty but reiterated domestic 30% growth and EBITDA margin guidance of 25-27%. Capex guidance maintained at Rs 250+ crore for two new plants. Key risk: further tariff escalation could impact export recovery trajectory.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹535 Cr
Source date
Pending
Across the record
Quarter history.
History modules